Domestic:+91 8550986868sales@anantlabs.com
LoginSign up
/
Anant Labs

Ruxolitinib

CAS 941678-49-5

Ruxolitinib
In Stock

Ruxolitinib

Cat. No. ANT-RXL-000CAS 941678-49-5In Stock
Technical Data
Cat. No.ANT-RXL-000
CAS941678-49-5
Mol. FormulaC17H18N6
Mol. Weight306.37 g/mol
IUPAC(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
SMILESC1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChIInChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
InChI KeyHFNKQEVNSGCOJV-OAHLLOKOSA-N
Purity99%
Description

Overview

Ruxolitinib, sold under the brand names Jakafi, Jakavi, and Opzelura is a medication used for the treatment of intermediate or high-risk myelofibrosis,a type of myeloproliferative disorder that affects the bone marrow; polycythemia vera (PCV), when there has been an inadequate response to or intolerance of hydroxyurea;and steroid-refractory acute graft-versus-host disease.Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi,and by Novartis elsewhere in the world, under the brand name Jakavi

Anant Labs manufacture and furnish high quality Ruxolitinib impurities for global markets. Our Ruxolitinib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.

Synonyms

NARuxolitinib941678-49-5INCB018424INCB-018424INCB18424INC42482S8X8XX8H(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrileINC-424

Looking for a specific reference standard?

Tell us what you need. Our team responds within one business day.